The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: a pathophysiological update
MA Nauck, DR Quast, J Wefers… - Diabetes, Obesity and …, 2021 - Wiley Online Library
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
The discovery and development of liraglutide and semaglutide
LB Knudsen, J Lau - Frontiers in endocrinology, 2019 - frontiersin.org
The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …
[HTML][HTML] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
T Coskun, KW Sloop, C Loghin, J Alsina-Fernandez… - Molecular …, 2018 - Elsevier
Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …
determine whether the metabolic action of GIP adds to the established clinical benefits of …
Incretin hormones: Their role in health and disease
MA Nauck, JJ Meier - Diabetes, Obesity and Metabolism, 2018 - Wiley Online Library
Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists
Context Obesity is responsible for an increased risk of sub-fecundity and infertility. Obese
women show poorer reproductive outcomes regardless of the mode of conception, and …
women show poorer reproductive outcomes regardless of the mode of conception, and …
[HTML][HTML] An inter-organ neural circuit for appetite suppression
Summary Glucagon-like peptide-1 (GLP-1) is a signal peptide released from
enteroendocrine cells of the lower intestine. GLP-1 exerts anorectic and antimotility actions …
enteroendocrine cells of the lower intestine. GLP-1 exerts anorectic and antimotility actions …
Glucagon-like peptide 1 in health and disease
In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials
MP Gilbert, RE Pratley - Frontiers in endocrinology, 2020 - frontiersin.org
The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …
Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB
The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …
management of obesity and type 2 diabetes mellitus and novel developments in …